Stay updated with breaking news from Cell Genomics Changes. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- The "Respiratory Infection Diagnostic Markets by Technology, Plex, Place, Product and by Region With Covid-19 Impact & Forecasting/Analysis,...
/PRNewswire/ -- The "Respiratory Infection Diagnostic Markets by Technology, Plex, Place, Product and by Region With Covid-19 Impact & Forecasting/Analysis,...
3.3.2 Bioinformatics Plays a Role 3.4 Diagnostic Technology Development 3.4.2 Single Cell Genomics Changes the Picture 3.4.3 Pharmacogenomics Blurs Diagnosis and Treatment 3.4.4 CGES Testing, A Brave New World 3.4.5 Biochips/Giant magnetoresistance based assay 4. Cancer Panels & Profiles Recent Developments 4.1 Recent Developments - Importance and How to Use This Section 4.1.1 Importance of These Developments 4.1.2 How to Use This Section Biocartis Collaborating With GeneproDx, Endpoint Health on Tests for Idylla Platform Wales to Routinely Screen Cancer Patients With Yourgene Elucigen...
Will Personalized Companion Diagnostics become the norm for diagnostics? Companion Diagnostics are poised to revolutionize the diagnostics industry. The market is finally moving out of the lab and into the clinic. Oncology, especially immune-oncology is leading the way. And the FDA is holding the door open for this diagnostic technology of the future. But COVID-19 is impacting healthcare treatment everywhere and lowering demand for specialized cancer testing. Find out the latest outlook for this important market. Learn all about how diagnostic players are jockeying for position with their pha...
Share this article Share this article ResearchAndMarkets.com's offering. The Multiplex factor is creating market confusion while lowering costs and improving care but important factors are holding back progress. COVID-19 has broken open the market for point of care testing of respiratory infections. Now the competition for market share begins in earnest. Large new markets are opening up. In health facilities, clinics, physicians' offices and elsewhere. And let's not forget the screening market, not just for COVID, but for the rest of the 20 something respiratory pathogens as well. Multiplex...